Literature DB >> 1353717

Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects.

D R Taylor1, G T Wilkins, G P Herbison, E M Flannery.   

Abstract

The aim of this study was to investigate whether the administration of prednisone potentiates any of the acute biochemical and cardiovascular effects of high-dose inhaled beta-agonist drugs. These agents are known to cause dose-related changes in plasma potassium and glucose, as well as ECG changes in heart rate, corrected QT interval (QTc), T wave, and U wave. On theoretical grounds, the concomitant use of systemic corticosteroids might enhance these actions. Twenty-four healthy subjects were randomized to receive one of three treatments: salbutamol 5 mg or fenoterol 5 mg or normal saline solution. Each drug was administered twice, 30 min apart by nebulizer, and the procedure was repeated after each subject had received prednisone 30 mg daily for one week. Plasma potassium and glucose levels were measured, and ECGs were obtained after each treatment, together with 12-h Holter monitoring for arrhythmias. Changes in plasma potassium and glucose following nebulized beta-agonist were significantly greater after treatment with prednisone. Baseline potassium level fell from 3.75 mmol/L (95 percent CI 3.61, 3.89) to 3.50 mmol/L (95 percent CI 3.36, 3.64), and thereafter all values were significantly lower at each time point (p = 0.003). The lowest mean plasma potassium was obtained 90 min after fenoterol administration with prednisone pretreatment: 2.78 mmol/L (95 percent CI 2.44, 3.13). Increases in heart rate and QTc interval following both beta-agonist drugs were significant, but T-wave amplitude reductions did not reach significance. Prednisone treatment did not significantly alter the cardiovascular responses. Supraventricular and ventricular ectopic activity was related to beta-agonist use, but no potentiating effect was noted following steroid treatment. We conclude that the acute biochemical effects of beta-agonist administration are augmented by prior treatment with prednisone, but this is not the case for ECG effects. However, the degree of hypokalemia noted as a result of this drug interaction may be of clinical significance in the hypoxic conditions of acute airways obstruction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353717     DOI: 10.1378/chest.102.2.519

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  Interactions between corticosteroids and beta agonists.

Authors:  D R Taylor; R J Hancox
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  Interactions between corticosteroids and beta2-agonists.

Authors:  Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

3.  Salbutamol and/or beclomethasone diproprionate in asthma.

Authors:  Sunita Sharma; Preeti Godatwar; L R Kulkarni
Journal:  Indian J Pediatr       Date:  2003-02       Impact factor: 1.967

Review 4.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

5.  Effect of Ventolin on QTc in children with respiratory distress.

Authors:  Mohammad Reza Khalilian; Abbas Fayezi; Mohsen Alisamir; Negar Mohammadi Khorasani
Journal:  J Cardiovasc Thorac Res       Date:  2016-06-28

6.  Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.

Authors:  Xia Chen; Xin Zheng; Ji Jiang; Pei Hu; Kai Wu; Lihong Zhuang; Lian Liu; Xin Du; Rodger Kempsford; Ann Allen
Journal:  Pharmacotherapy       Date:  2015-06-09       Impact factor: 4.705

7.  Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.

Authors:  Eugene Jeong; Scott D Nelson; Yu Su; Bradley Malin; Lang Li; You Chen
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.